Recent Updates
Recently added Catalysts

Merus N.V.

MRUSFDA catalysts, PDUFA dates & pipeline intelligence
$90
▼ -6.86 · -7.08%

Last traded Dec 29, 2025. This price is not current.

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full MRUS financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $33.1952W HIGH $97.14
Volume
2.73 M
Value Traded
252.72 M
Short % Float
1.17%
Days to Cover
1.0
-7.12%Week
-6.35%1 Month
-3.87%3 Month
+71.33%6 Month
+418.73%5 Year
+823.08%All Time

Cash Data

Unlock MRUS cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
6.83 B
EPS (TTM)
-5.33
P/E Ratio
-
Ent. Value
6.20 B
Total Shares
75.63 M
Float Shares
69.95 M
Insiders
10.96%
Institutions
90.07%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Phase 3 topline data readout
petosemtamab
Combination with pembrolizumab
Phase 3BiologicsOncology
Unlock every MRUS catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

MRUS Catalyst Timeline

Dated clinical, regulatory and corporate events for Merus N.V.

Unlock the full MRUS catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How MRUS actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-05-08Bizengri (zenocutuzumab-zbco) PDUFA Date ApprovedPDUFA
Unlock 5 more MRUS historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Commercial Value
Valuation Signal
2
Drugs Scored
rNPV / MCap
Top Drug
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Sep 2025)
Showing 4 of 4 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
Petosemtamab Monoclonal antibodyNCT06525220Head and Neck Squamous Cell CarcinomaPhase 3 ACTIVE NOT_RECRUITING 1,320Jul 1, 2030
Petosemtamab Monoclonal antibodyNCT03526835Advanced/Metastatic Solid TumorsPhase 1/2 RECRUITING 560Nov 1, 2028
MCLA-145 Small moleculeCompletedNCT03922204Advanced CancerPhase 1 COMPLETED 72Nov 7, 2024
Zenocutuzumab Monoclonal antibodyNot countedNCT03321981Breast Cancer MetastaticPhase 2 COMPLETED 105Jul 26, 2023
Unlock the MRUS pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every MRUS program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
petosemtamab
BreakthroughFast Track
metastatic colorectal cancerPhase 22025-10-25100% responspercentage in 1L linkszijdige mCRC (n=8, bevestigd en onbevestigd); 62% responspercentage in 2L links- en rechtszijdige mCRC (n=13, bevestigd en onbevestigd)Read MoreTussentijdse gegevens van Merus over petosemtamab bij gemetastaseerde colorectale kanker tonen monotherapie-activiteit en robuust responspercentage aan in combinatie met FOLFOX/FOLFIRI, alsook goed verdragen veiligheidRead More
Scroll for more · summaries link to the source press release
Unlock every MRUS trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock MRUS insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
GENMAB A/S10% OwnerBuy 1,052,806 73,884,293 held$97.00 12/29/2025
Unlock the full MRUS insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Hedge Funds invested in MRUS

Fund % of Portfolio Current MV Shares Owned Activity
Paradigm Biocapital Advisors LP 11.7 % (21.9 %) 411.79 M 4.37 M 2.14% ( 91.82 K)
Unlock every fund holding MRUS
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in MRUS
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see MRUS ownership
Insider and institutional ownership, quarter by quarter.

MRUS Short Interest

Shares sold short, counted twice a month.

1.17%
Short % of Float
of tradable shares sold short
817.9K
Shares Sold Short
-48.0% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
1.3M
Avg Daily Volume
the average used for days to cover
Unlock MRUS short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock MRUS option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live MRUS option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock MRUS options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How MRUS ranks across every disease it competes in

Competitive Position is a premium feature
See how MRUS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

MRUS News

About Merus N.V.

Founded2016
BIOPHARMAWATCH ELITE PLUS
Trade the next MRUS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime